The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Yes that’s a fair enough explanation from a trading point of view but it does not account for the fact that a significant number of traders ultimately lose money. Traders create liquidity but the biggest gains are made from investors who identify a growth stock and average down with the fluctuations
Looks like 5 patients presently being dosed in DE7. Quick turn around there
Avacta will be bought out well before 2026
Better than expected cash position, groundbreaking technology that will create a paradigm shift in chemo treatment, pipeline of further drugs looking strong with more details soon, growing diagnostic programme and marketing opportunities, all looking very positive for anyone with half a brain
I had a similar reaction when I sent this week’s news to a pal of mine who was a previous CEO in a Plc and has been an investor in the stock market since the 80’s. He went straight to the Financials and Broker notes and said he would invest only a small sum because it was high risk. Like HL’s frequent E mails to me he was horrified at my high exposure. Never been more confident
Worth listening to and for once a very fair assessment of yesterday’s developments from a financial commentator
Great interview emphasising non dilutive funding being aimed for and reduced costs with the shorter timeframe.
No p1b
Many of us have learnt a lot more from Myles’research over the years than your often cynical, spiteful comments
The North won’t need to join in they are already here!
*************c/1542528041/32812
a good positive recent interview for those who haven’t seen it
I am sure if you were ultimately in the unfortunate position of benefiting from the Precision programme you would take a very different view of his financial package
Instead of rushing to judgment we should wait for the AGM when Al previously stated that he would spend time explaining the strategy and progress made re the diagnostic division
Looks very impressive to my untrained eye
News Friday or Monday then. I am finally allowing myself to become excited
The Science day will be when all the data is available which may or may not be in November. A key event whenever the date
The negative opinions are not the issues it is the manner in which they are sometimes made and the banter which some regulars think is humorous and others think it childish and at times pathetic
Given the present market sentiment P1 results could be sold into on the spike. Aim traders live off fears of imminent dilution and if those results were to be followed by Traceda licensing AV3996 that would remove that threat and could provide a floor for the SP at a much higher level
Al said at the last Presentation that the diagnostic side of the business will be revenue generating from next year. It is highly unlikely that the tests they are presently developing will be as dependent on the vagaries of the Government like the ill fated covid test. Whilst we all righty concentrate on AVA6K the diagnostic side could very well pleasantly surprise us next year
Great reference for Avacta as part of a world life science cluster
https://www.standard.co.uk/business/dog-track-is-gone-but-white-city-is-racing-ahead-b1005103.html